Bicyclol

Drug Profile

Bicyclol

Alternative Names: SY 801

Latest Information Update: 13 Jul 2015

Price : $50

At a glance

  • Originator Chinese Academy of Medical Sciences
  • Developer Beijing Union Pharmaceutical; Chinese Academy of Medical Sciences
  • Class Antineoplastics; Antivirals; Biphenyl compounds; Hepatoprotectants; Small molecules
  • Mechanism of Action Cytochrome P-450 enzyme system stimulants; Free radical scavengers; Gap junction modulators; Glutathione transferase stimulants; HSP70 heat shock protein stimulants; Protein kinase C inhibitors; Proto-oncogene protein c-myc stimulants; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fatty liver; Viral hepatitis
  • Preclinical Liver cancer

Most Recent Events

  • 13 Jul 2015 Bicyclol is covered by patent protection (Beijing Union website, July 2015)
  • 18 Nov 1996 Preclinical development for Viral hepatitis in China (Unknown route)
  • 15 Nov 1996 Preclinical development for Liver cancer in China (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top